(Q36948475)

17 August 2017

title

The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia (English)

1 reference

17 August 2017

1 reference

1 reference

9

Daniel Catovsky

1 reference

17 August 2017

4

Claire Dearden

1 reference

17 August 2017

6

Estella Matutes

1 reference

17 August 2017

1

Monica Else

1 reference

17 August 2017

7

Andrew Wotherspoon

1 reference

17 August 2017

2

Nnenna Osuji

1 reference

17 August 2017

5

Ilaria Del Giudice

1 reference

17 August 2017

3

Francesco Forconi

1 reference

17 August 2017

Francesco Lauria

8

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

110

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

2240-2247

1 reference

2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Towards the pharmacotherapy of hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Efficacy of rituximab in hairy cell leukemia treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Rituximab in relapsed or refractory hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Rituximab as treatment for minimal residual disease in hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Eradication of minimal residual disease in hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

BL22 and lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Monoclonal antibody therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Treatment of resistant/relapsing chronic lymphocytic leukemia with a combination regimen containing deoxycoformycin and rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Prognosis of High Dose Chemotherapy/Autologous Bone Marrow Transplantation Candidates not Receiving This Treatment after Failure of Primary Therapy of Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Cladribine (2-chlorodeoxyadenosine)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long‐term follow‐up study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Immunophenotyping and differential diagnosis of hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Current treatment options in hairy cell leukemia and hairy cell leukemia variant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.23032

1 reference

7 January 2021

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23032

7 January 2021

Identifiers

DOI

10.1002/CNCR.23032

1 reference

17 August 2017

1 reference